Anna Kron

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler, Michaela A. Ihle, Rebecca Hein et al. · Journal of Thoracic Oncology · 2018 · 259 citations · Full text

Medicine, Genetics, Oncology +17

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Anna Kron, Christina Alidousty, Matthias Scheffler et al. · Annals of Oncology · 2018 · 211 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Clinical and Pathological Characteristics of <i>KEAP1</i> - and <i>NFE2L2</i> -Mutated Non–Small Cell Lung Carcinoma (NSCLC)

Rieke Frank, Matthias Scheffler, Sabine Merkelbach‐Bruse et al. · Clinical Cancer Research · 2018 · 166 citations

Medicine, Genetics, Oncology +17

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

Jana Fassunke, Fabienne Müller, Marina Keul et al. · Nature Communications · 2018 · 139 citations · Full text

Medicine, Oncology, Pharmacology +15

Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial

Sebastian Michels, Bartomeu Massutí, Hans‐Ulrich Schildhaus et al. · Journal of Thoracic Oncology · 2019 · 131 citations · Full text

Medicine, Oncology, Pharmacology +14